The Cancer Vaccine That Could Save Moderna
Summary
Moderna’s stock has plummeted 90% as COVID vaccine sales waned, but recent promising Phase 3 results for its personalized melanoma vaccine have revived investor hope. The episode details Moderna’s risky pivot from infectious diseases to oncology, a journey fueled by early investor support and a partnership with Merck. Despite pandemic-era setbacks and financial struggles, this breakthrough positions Moderna as a potential leader in cancer treatment, marking a critical turning point for the biotech firm.
Topics discussed
Moderna's stock crash and surprising cancer vaccine news
Show intro and sponsor advertisements
Moderna's origins and early hesitation on cancer research
Internal debate and investor funding for oncology program
Partnership with Merck and Phase 2 study launch
Pandemic pivot, financial boom, and post-COVID struggles
Promising Phase 2 results and successful Phase 3 trial
Company celebration and future FDA approval hopes
New podcast series promo and episode credits
Listen ad-free on Castria